FDA Conditionally Accepted Name for New Cancer Drug
The oral medication Lirafugratinib, proposed as LYRFIGTU, is currently being reviewed for treating bile duct cancer.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to prioritize patient health over branding in drug development?
The FDA has conditionally accepted the name LYRFIGTU for Lirafugratinib, an oral targeted anticancer agent. A regulatory decision regarding the drug's approval is expected to occur this fall.
Why it matters
This development marks a step forward in the potential availability of a new targeted therapy for bile duct cancer. The medication is designed to address specific genetic drivers of tumor growth.
In clinical trials for patients with bile duct cancer, the treatment demonstrated an objective response rate of 46.5 percent with a median duration of response lasting 11.8 months. These findings grounded the drug's path through the regulatory review process.
The players
FDA
The federal agency responsible for regulating pharmaceuticals, medical devices, and public health safety in the United States.
Lirafugratinib
An oral small-molecule targeted anticancer agent currently undergoing regulatory review for bile duct cancer.
The details
Lirafugratinib functions as a small-molecule targeted agent designed to inhibit the FGFR2 genetic mutation that drives cancer cell proliferation. By specifically targeting these FGFR2 mutations, the drug aims to stop tumor growth at the cellular level. The name LYRFIGTU was selected to reflect this focus on selectivity for the FGFR2 protein.
Timeline
2022: Lirafugratinib received Orphan Drug designation.
2023: The FDA granted Innovative Therapy designation.
March 2026: Lirafugratinib was selected for Priority Review.
September 21, 2026: The FDA conditionally accepted the proposed product name.
September 25, 2026: The FDA is scheduled to announce its approval decision.
Health Landscape
This drug enters a landscape where targeted therapies are increasingly used to treat cancers with specific genetic mutations. Its development follows the framework established by the FDA's Orphan Drug designation program to expedite treatments for rare conditions.
If you are managing bile duct cancer, this drug remains under regulatory review and is not yet available for clinical use. You may want to discuss the potential availability of targeted therapies with your oncologist to determine if your specific tumor profile makes you a candidate for future trials.
The takeaway
Targeted therapies like Lirafugratinib continue to evolve by addressing the specific genetic mutations driving bile duct cancer. Patients and caregivers should keep track of the upcoming FDA announcement on September 25 and consult their primary care oncologist regarding the latest treatment options.
What happens next
The FDA is scheduled to announce its final approval decision for Lirafugratinib on September 25, 2026.
Further reading
For more on the current research landscape, visit the Cancer section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health over branding in drug development?
